A Randomized, Single-Dose, Open-Label, Parallel-Group Study to Determine the Relative Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA in Schizophrenia Patients
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2019
Price : $35 *
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Luye Pharma Group
- 12 Aug 2019 Status changed from active, no longer recruiting to completed.
- 30 Jul 2019 Planned End Date changed from 30 Jun 2019 to 26 Jul 2019.
- 30 Jul 2019 Planned primary completion date changed from 30 Jun 2019 to 26 Jul 2019.